Advice
following an abbreviated submission:
indacaterol maleate plus glycopyrronium bromide inhalation powder hard capsules (Ultibro® Breezhaler®) is accepted for use within NHS Scotland.
Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
For patients in whom the combination of indacaterol maleate and glycopyrronium bromide is an appropriate choice of therapy, Ultibro® Breezhaler® provides the two ingredients in a single hard capsule at a lower cost than the individual components.
Download detailed advice41KB (PDF)
Medicine details
- Medicine name:
- indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler)
- SMC ID:
- 922/13
- Indication:
- maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 December 2014